Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling

Endocrinology

Volumn 141, Issue 11, 2000, Pages 4171-4179

  Devi, G R ^a   Yang, D H ^a   Rosenfeld, R G ^a   Oh, Y ^a  

^a AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL SURFACE; INSULIN LIKE ACTIVITY; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING;

ESCHERICHIA COLI;

EID: 0033713982     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.141.11.7781     Document Type: Article

References (48)

1. Insulin-like growth factors and their binding proteins: Biological actions
2. The insulin-like growth factor binding protein superfamily: New perspectives
3. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells
4. Transfection of the human IGFBP-3 gene into Balb/c fibroblasts: A model for the cellular functions of IGFBPs
5. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene
6. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells
7. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-b1 on programmed cell death through a p53- and IGF-independent mechanism
8. The Type V transforming growth factor b receptor is the putative insulin-like growth factor-binding protein 3 receptor
9. Insulin-like growth factor binding protein (IGFBP) proteases: Functional regulators of cell growth
10. IGFBP-3 proteolysis by plasmin, thrombin, serum: Heparin binding, IGF binding, and structure of fragments
11. Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex
12. Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: A possible role for insulin in the regulation of IGFBP-3 protease activity
13. The insulin-like growth factor axis and growth in children with chronic renal failure: A report of the Southwest Pediatric Nephrology Study Group
14. Human pregnancy serum contains at least two distinct proteolytic activities with the ability to degrade insulin-like growth factor binding protein-3
15. Insulin-like growth factor binding protein-3 concentrations and I.-l. growth factor binding protein-3 protease activity in sera of patients with malignant solid tumors or leukemia
16. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) proteolysis in patients with colorectal cancer: Possible association with the metastatic potential of the tumor
17. Biological actions of proteolytic fragments of the IGFBPs
18. Evidence that limited proteolysis of insulin-like growth factor binding protein-3 (IGFBP-3) occurs in the normal state outside of the bloodstream
19. Active and inhibitory components of the insulin-like growth factor binding protein-3 protease system in adult serum, interstitial, and synovial fluid
20. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin
21. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins
22. Insulin and IGF binding by IGFBP-3 fragments derived from proteolysis, baculovirus expression and normal human urine
23. Characterization of truncated insulin-like growth factor-binding protein-2 in human milk
24. Isolation and characterization of circulating 13-kDa C-terminal fragments of human insulin-like growth factor binding protein-5
25. Synthesis of IGFBP-3 fragments in a baculovirus system and characterization of monoclonal anti-IGFBP-3 antibodies
26. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells
27. Synthesis and characterization of insulin-like growth factor binding protein (IGFBP-7)
28. Analysis of serum insulin-like growth factor binding proteins using western blotting: Use of the method for titration of the binding proteins and competitive binding studies
29. Isolation and NH2-terminal amino acid sequences of rat serum carrier proteins for insulin-like growth factors
30. Insulin-like growth factor binding proteins: A proposed superfamily
31. Recommendations for nomenclature for the insulin-like growth factor binding protein (IGFBP) superfamily
32. The insulin-like factor binding protein (IGFBP) superfamily
33. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action
34. Glucocorticoid regulation of an insulin-like growth factor-binding protein-4 protease produced by a rat neuronal cell line
35. Proteolytic cleavage of insulin-like growth factor binding protein 4 (IGFBP-4): Localization of cleavage sit to non-homologous region of native IGFBP-4
36. Human osteoblast-derived insulin-like growth factor (IGF) binding protein 5 stimulates osteoblast mitogenesis and potentiates IGF action
37. Carboxy-truncated insulin-like growth factor binding protein-5 stimulates mitogenesis in osteoblast-like cells
38. Structure-function analysis of the human insulin-like growth factor binding protein-4
39. Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IGFBP-1)
40. Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3
41. Characterization of glycosaminoglycan-binding domains present in insulin-like growth factor-binding protein-3
42. Amino acids within the extracellular matrix (ECM) binding region (201-218) of rat insulin-like growth factor binding protein (IGFBP-5) are important determinants in binding IGF-I
43. An insulin-like growth factor II (IGF-II) affinity-enhancing domain localized within extracytoplasmic repeat 13 of the IGF-II/mannose 6-phosphate receptor
44. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains
45. Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex
46. The cytoskeletal protein talin contains at least two distinct vinculin binding domains
47. Thyroglobulin type-1 domains in equistatin inhibit both papain-like cysteine proteinases and cathepsin D
48. Heparin-binding, highly basic regions within the thyroglobulin type-I repeat of insulin-like growth factor (IGF)-binding proteins (IGFBPs) -3, -5, and -6 inhibit IGFBP-4 degradation